Table 2.
Demographic and clinical variables for the FTD patients and controls
| Groups | n | Gender, male | Age at scan (years) | Disease duration (years) | |
|---|---|---|---|---|---|
| Controls | 104 | 44% | 62.5 (10.4) | — | |
| Clinical (n = 402) | FTD‐MND | 8 | 63% | 66.9 (4.3) | 5.3 (2.9) |
| bvFTD | 180 | 68% | 62.3 (8.0) | 5.2 (3.2) | |
| nfvPPA | 114 | 46% | 67.5 (8.7) | 4.4 (2.5) | |
| PPA‐NOS | 15 | 67% | 64.2 (6.1) | 3.3 (1.7) | |
| svPPA | 85 | 56% | 63.9 (7.2) | 4.8 (2.5) | |
| Genetica (n = 73) | C9orf72 | 28 | 68% | 62.8 (5.9) | 5.5 (3.3) |
| GRN | 18 | 56% | 62.0 (6.3) | 3.1 (2.6) | |
| MAPT | 27 | 63% | 55.9 (7.5) | 5.7 (3.2) | |
| Pathologicala (n = 79) | TDP‐43 type A | 15 | 60% | 62.1 (5.8) | 3.3 (1.7) |
| TDP‐43 type B | 3 | 67% | 57.1 (7.7) | 4.8 (2.7) | |
| TDP‐43 type C | 20 | 65% | 65.3 (7.3) | 4.7 (2.8) | |
| FTDP‐17 | 7 | 71% | 51.3 (5.8) | 5.2 (3.1) | |
| tau‐Pick's | 17 | 76% | 59.7 (4.2) | 4.4 (2.2) | |
| tau‐PSP | 4 | 100% | 76.9 (7.3) | 5.1 (3.9) | |
| tau‐CBD | 9 | 78% | 61.8 (9.1) | 4.5 (0.9) | |
| FUS | 4 | 75% | 45.7 (11.7) | 3.0 (1.8) | |
Note: Values denote mean (SD) or n (%).
a
Genetic and pathological cohorts are subsets of the overall clinical cohort with some overlap between the two (n = 20).